These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 32976576)

  • 21. ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease.
    Jagasia M; Lazaryan A; Bachier CR; Salhotra A; Weisdorf DJ; Zoghi B; Essell J; Green L; Schueller O; Patel J; Zanin-Zhorov A; Weiss JM; Yang Z; Eiznhamer D; Aggarwal SK; Blazar BR; Lee SJ
    J Clin Oncol; 2021 Jun; 39(17):1888-1898. PubMed ID: 33877856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease.
    Nahas MR; Soiffer RJ; Kim HT; Alyea EP; Arnason J; Joyce R; Antin JH; Ho VT; Stroopinsky D; Li S; Levine JD; McMasters M; Jain S; Hamdan A; Tzachanis D; Bryant MP; Logan EK; Bazemore J; Stewart J; Joyce A; Stephenson S; Washington A; Cole L; Pyzer A; Leaf RK; Avigan DE; Rosenblatt J
    Blood; 2018 Jun; 131(25):2836-2845. PubMed ID: 29549175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P;
    Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
    Wolschke C; Stübig T; Hegenbart U; Schönland S; Heinzelmann M; Hildebrandt Y; Ayuk F; Atanackovic D; Dreger P; Zander A; Kröger N
    Exp Hematol; 2013 Feb; 41(2):134-142.e3. PubMed ID: 23085463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
    Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC
    Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD.
    Jagasia M; Scheid C; Socié G; Ayuk FA; Tischer J; Donato ML; Bátai Á; Chen H; Chen SC; Chin T; Boodée H; Mitri G; Greinix HT
    Blood Adv; 2019 Jul; 3(14):2218-2229. PubMed ID: 31332045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
    Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
    Harrison SJ; Perrot A; Alegre A; Simpson D; Wang MC; Spencer A; Delimpasi S; Hulin C; Sunami K; Facon T; Vlummens P; Yong K; Campana F; Inchauspé M; Macé S; Risse ML; van de Velde H; Richardson P
    Br J Haematol; 2021 Jul; 194(1):120-131. PubMed ID: 34036560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.
    Kneppers E; van der Holt B; Kersten MJ; Zweegman S; Meijer E; Huls G; Cornelissen JJ; Janssen JJ; Huisman C; Cornelisse PB; Bruijnen CP; Emmelot M; Sonneveld P; Lokhorst HM; Mutis T; Minnema MC
    Blood; 2011 Sep; 118(9):2413-9. PubMed ID: 21690556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hydrogen in Patients With Corticosteroid-Refractory/Dependent Chronic Graft-Versus-Host-Disease: A Single-Arm, Multicenter, Open-Label, Phase 2 Trial.
    Qian L; Liu M; Shen J; Cen J; Zhao D
    Front Immunol; 2020; 11():598359. PubMed ID: 33324415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease.
    Arora M; Wagner JE; Davies SM; Blazar BR; Defor T; Enright H; Miller WJ; Weisdorf DF
    Biol Blood Marrow Transplant; 2001; 7(5):265-73. PubMed ID: 11400948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The concurrent administration of imatinib with extracorporeal photopheresis leads to complete and durable responses in patients with refractory sclerotic type chronic graft-versus-host disease.
    Alsuliman T; Magro L; Coiteux V; Gauthier J; Srour M; Lionet A; Beauvais D; Yakoub-Agha I
    Curr Res Transl Med; 2020 Apr; 68(2):71-76. PubMed ID: 31631014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial.
    Jagasia M; Perales MA; Schroeder MA; Ali H; Shah NN; Chen YB; Fazal S; Dawkins FW; Arbushites MC; Tian C; Connelly-Smith L; Howell MD; Khoury HJ
    Blood; 2020 May; 135(20):1739-1749. PubMed ID: 32160294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclophosphamide for salvage therapy of chronic graft-versus-host disease: a retrospective analysis.
    Fante MA; Holler B; Weber D; Angstwurm K; Bergler T; Holler E; Edinger M; Herr W; Wertheimer T; Wolff D
    Ann Hematol; 2020 Sep; 99(9):2181-2190. PubMed ID: 32715339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Skin ulcers related to chronic graft-versus-host disease: clinical findings and associated morbidity.
    Jachiet M; de Masson A; Peffault de Latour R; Rybojad M; Robin M; Bourhis JH; Xhaard A; Dhedin N; Sicre de Fontbrune F; Suarez F; Barete S; Parquet N; Nguyen S; Ades L; Rubio MT; Wittnebel S; Bagot M; Socié G; Bouaziz JD
    Br J Dermatol; 2014 Jul; 171(1):63-8. PubMed ID: 24404963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High Response Rate and Corticosteroid Sparing with Arsenic Trioxide-Based First-Line Therapy in Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
    Rongvaux-Gaïda D; Dupuis M; Poupon J; Djebrani-Oussedik N; Lemonnier C; Rieger F
    Transplant Cell Ther; 2022 Oct; 28(10):679.e1-679.e11. PubMed ID: 35830931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Open-Label, Multicenter Phase II Study of Combination Therapy of Imatinib Mesylate and Mycophenolate Mofetil in Pediatric Patients with Steroid-Refractory Sclerotic/Fibrotic Type Chronic Graft-versus-Host Disease.
    Choi JY; Kim H; Baek HJ; Kook H; Lee JM; Kim BK; An HY; Hong KT; Shin HY; Kang HJ
    Transplant Cell Ther; 2021 Nov; 27(11):925.e1-925.e7. PubMed ID: 34314892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.
    Tefferi A; Al-Ali HK; Barosi G; Devos T; Gisslinger H; Jiang Q; Kiladjian JJ; Mesa R; Passamonti F; McMullin MF; Ribrag V; Schiller G; Vannucchi AM; Zhou D; Reiser D; Zhong J; Gale RP
    Leukemia; 2017 Apr; 31(4):896-902. PubMed ID: 27773929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.
    Koreth J; Kim HT; Jones KT; Lange PB; Reynolds CG; Chammas MJ; Dusenbury K; Whangbo J; Nikiforow S; Alyea EP; Armand P; Cutler CS; Ho VT; Chen YB; Avigan D; Blazar BR; Antin JH; Ritz J; Soiffer RJ
    Blood; 2016 Jul; 128(1):130-7. PubMed ID: 27073224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Multicenter, Retrospective Study Evaluating Clinical Outcomes of Ruxolitinib Therapy In Heavily Pretreated Chronic GVHD Patients With Steroid Failure.
    White J; Elemary M; Linn SM; Novitzky-Basso I; Culos S; Tan SK; Kelly K; Deotare U; Xenocostas A; Hamad N; Law A; Kumar R; Kim DDH
    Transplant Cell Ther; 2023 Feb; 29(2):120.e1-120.e9. PubMed ID: 36460202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.